| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | Michael J Sorich | |
| Ross A McKinnon | |||
| Mafalda M Dias | |||
| P2860 | cites work | The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer | Q43106213 |
| Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism | Q44637207 | ||
| UGT1A and irinotecan toxicity: keeping it in the family | Q46052031 | ||
| Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 | ||
| Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. | Q46605316 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy | Q27851574 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy | Q27863360 | ||
| Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study | Q33383787 | ||
| Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. | Q33384024 | ||
| Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. | Q33783293 | ||
| Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. | Q33990876 | ||
| Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer | Q34565071 | ||
| Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. | Q34975510 | ||
| UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. | Q36785973 | ||
| Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question | Q37249563 | ||
| Methodological quality of pharmacogenetic studies: issues of concern | Q37287588 | ||
| Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? | Q37345971 | ||
| Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review | Q37345974 | ||
| UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer | Q37402459 | ||
| Assessing tumor response to therapy | Q37452321 | ||
| Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis | Q37718359 | ||
| Molecular predictive and prognostic markers in colon cancer | Q37723882 | ||
| UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma | Q40426198 | ||
| Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk | Q43012426 | ||
| Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. | Q43102323 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetics | Q7162 |
| irinotecan | Q412197 | ||
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 889-899 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis | |
| P478 | volume | 13 |
| Q62835353 | A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients |
| Q53280262 | A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). |
| Q35603648 | An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients |
| Q34629650 | Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians |
| Q45590471 | Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features. |
| Q26768427 | Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances |
| Q43358640 | Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. |
| Q26851060 | FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy |
| Q36365599 | Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations. |
| Q42714050 | Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting |
| Q34981428 | Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups |
| Q92795015 | Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomark |
| Q38922471 | Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q28068930 | Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use |
| Q45456321 | Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients. |
| Q58796906 | Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study |
| Q98771157 | Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy |
| Q35021702 | SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer |
| Q36990461 | Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients |
| Q48027272 | The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance |
| Q38202816 | The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis |
| Q51040976 | The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. |
| Q90179413 | Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease |
| Q38393997 | UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. |
| Q37682812 | UGT1A1 polymorphisms in cancer: impact on irinotecan treatment |
| Q38787385 | UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis |
Search more.